Kreke Michelle, Smith Rachel Ruckdeschel, Marbán Linda, Marbán Eduardo
Capricor, Inc., Los Angeles, CA 90048, USA.
Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1185-94. doi: 10.1586/erc.12.102.
Heart disease is a major cause of morbidity and mortality. Cellular therapies hold significant promise for patients with heart disease. Heart-derived progenitor cells are capable of repairing a diseased heart through modulation of growth factor milieu and temporary engraftment leading to endogenous repair. The proof-of-concept CADUCEUS clinical trial using cardiosphere-derived cells has shown evidence of therapeutic cardiac tissue regeneration. Future clinical trials are now being planned to generate additional safety and efficacy data in the hopes of building toward an approved cellular therapy for heart disease.
心脏病是发病和死亡的主要原因。细胞疗法对心脏病患者具有重大前景。心脏来源的祖细胞能够通过调节生长因子环境和短暂植入来修复患病心脏，从而实现内源性修复。使用心球衍生细胞的概念验证性CADUCEUS临床试验已显示出治疗性心脏组织再生的证据。目前正在计划开展未来的临床试验，以获取更多安全性和有效性数据，期望朝着批准用于心脏病的细胞疗法迈进。
